Bisphosphonates: from the laboratory to the clinic and back again (Q33697467)

28 July 2017

1 reference

title

Bisphosphonates: from the laboratory to the clinic and back again (English)

1 reference

28 July 2017

0 references

Russell RG

1

1 reference

28 July 2017

Rogers MJ

series ordinal

2

1 reference

28 July 2017

publication date

1 July 1999

1 reference

28 July 2017

1 reference

28 July 2017

volume

25

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

97-106

1 reference

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The acute-phase response after bisphosphonate administration

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Human osteoclast formation and activity in vitro: effects of alendronate.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H( )-ATPase

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Reduction in new metastases in breast cancer with adjuvant clodronate treatment

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Isolation from urine of pyrophosphate, a calcification inhibitor

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Rho GTPases and the Actin Cytoskeleton

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Protein prenylation: a mediator of protein-protein interactions

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates as anticancer drugs

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Alendronate inhibition of protein-tyrosine-phosphatase-meg1

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideum

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Overview of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Diphosphonates in Paget's disease

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Diphosphonates and Page's disease of bone.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Regulation of osteoclast function

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Intermittent cyclical etidronate treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Rab GTPases in vesicular transport

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Protein prenylation: molecular mechanisms and functional consequences

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin

1 reference

https://api.crossref.org/works/10.1016/S8756-3282(99)00116-7

7 January 2021

10.1016/S8756-3282(99)00116-7

Identifiers

DOI

1 reference

28 July 2017

1 reference